Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHeiq Regulatory News (HEIQ)

  • There is currently no data for HEIQ

Director / PDMR Dealing

10 Jan 2023 07:00

RNS Number : 1634M
HeiQ PLC
10 January 2023
 

10 January 2023

 

HeiQ Plc

("HeiQ" or "the Company")

Director / PDMR Dealing

HeiQ Plc (LSE: HEIQ), a leading company in materials innovation and hygiene technologies, has been notified that on 9 January 2023, Carlo Centonze, Chief Executive Officer of the Company, purchased 25,000 ordinary shares in the Company ("Ordinary Shares") at a price of 34 pence per share. 

Following the purchase, Mr. Centonze holds an interest in 14,473,317 Ordinary Shares, including 5,186,237 Ordinary Shares held by Cortegrande AG, a company wholly owned by Mr. Centonze. The total interest held by Mr. Centonze represents approximately 10.33 per cent. of the Company's issued ordinary share capital.

This announcement, including the notification below, is made in accordance with the requirements of the UK Market Abuse Regulation.

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Mr. Carlo Centonze

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Chief Executive Officer

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

HeiQ plc

b)

 

LEI

 

 

213800IGT65IMJDO4S03

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

 

Ordinary Shares of 30 pence each

 

 

GB00BN2CJ299

 

b)

 

Nature of the transaction

 

 

Purchase of Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

34.0 pence

25,000

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

N/A

 

 

 

 

 

e)

 

Date of the transaction

 

 

9 January 2023

f)

 

Place of the transaction

 

 

London Stock Exchange, Main Market

 

 For further information, please contact:

HeiQ Plc

Carlo Centonze (CEO)

+41 56 250 68 50

Cenkos Securities plc (Joint Broker)

Stephen Keys / Callum Davidson

+44 (0) 207 397 8900

SEC Newgate (Media Enquiries)

Elisabeth Cowell / Axaule Shukanayeva / Molly Gretton

+44 (0) 20 3757 6882

HeiQ@secnewgate.co.uk

 

About HeiQ

HeiQ is focused on improving the lives of billions of people world-wide by innovating the materials people use every day. HeiQ has strong IP which is at the forefront of global technology in the $10 billion antimicrobial fabrics market, $24 billion textile chemicals market, the $50 billion probiotics market and the $150 billion man-made fibres market. It has also moved into the medical device, healthcare and hygiene coatings markets, to help make hospitals and healthcare environments more hygienic. HeiQ aims to deliver growth for its shareholders through a combination of increased sales of its core products and by entering additional lucrative markets through disruptive innovations and M&A.

HeiQ has created some of the most effective, durable and high-performance technologies in the market today, which cool, warm, dry, repel, purify, and destroy viruses. Since 2005, HeiQ has developed over 200 technologies in partnership with 300 major brands and it has a significant R&D pipeline containing over 50 projects. The Company has won multiple awards and gained a strong reputation for the ESG & sustainable downstream effect of its innovations. HeiQ is the only company to have won the Swiss Technology award twice. It has also won the Swiss Environmental award with an innovation that saves energy and water consumption during the textile manufacturing process.

Led by an experienced leadership team, HeiQ researches new solutions for partners, delivers scaled up manufacturing from its sites across the world and helps partners market the product to end consumers - aiming for lab to consumer in months.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUKUARONUARUR
Date   Source Headline
18th Nov 20247:00 amRNSDirector/PDMR Shareholding
14th Nov 20247:00 amRNSUpdate on Delisting and Potential Capital Raise
31st Oct 20247:01 amRNSNotice of AGM
31st Oct 20247:00 amRNSResults for 18-month period ended 30 June 2024
24th Oct 202411:26 amRNSHolding(s) in Company
22nd Oct 20247:00 amRNSRestructuring and Delisting
18th Sep 202411:45 amRNSHolding(s) in Company
16th Sep 20249:03 amRNSDirector/PDMR Shareholding
12th Sep 20247:00 amRNSTrading Update
16th Jul 20247:00 amRNSHeiq AeoniQ Capital Raising
30th May 20247:00 amRNSChange of Auditor
22nd Apr 20247:00 amRNSHeiQ Synbio Secures Ecolab Contract Win
16th Apr 20242:17 pmRNSHolding(s) in Company
28th Mar 20247:00 amRNSUnaudited Interim Results
18th Mar 202412:41 pmRNSHolding(s) in Company
15th Mar 20247:00 amRNSHolding(s) in Company
14th Mar 20241:23 pmRNSCompletion of Fundraising, PDMR & Audit Update
13th Mar 20242:26 pmRNSResult of General Meeting
12th Mar 20247:00 amRNSBoard Changes
23rd Feb 20247:00 amRNSResult of Retail Offer
16th Feb 20247:00 amRNSResult of Placing
15th Feb 20245:49 pmRNSRetail Offer
15th Feb 20245:46 pmRNSAcquisition, Fundraising, Trading Update & GM
6th Dec 20232:46 pmRNSAgreed Changes to Concert Party
4th Dec 20237:00 amRNSDirector/PDMR Dealing
1st Dec 20233:04 pmRNSResult of General Meeting
30th Nov 20237:06 amRNSStatement Confirming Settlement
27th Nov 20237:00 amRNSBoard Appointment
8th Nov 20237:00 amRNSNotice of General Meeting
3rd Nov 20239:14 amRNSHolding(s) in Company
3rd Nov 20237:05 amRNSHolding(s) in Company
31st Oct 20237:43 amRNSFiling of Annual Report & Restoration of Trading
31st Oct 20237:30 amRNSRestoration - HEIQ PLC
30th Oct 20237:01 amRNSInterim Results
30th Oct 20237:00 amRNSResults for year ended 31 December 2022
23rd Oct 20237:00 amRNSNotice of Results and Audit Update
29th Sep 20237:00 amRNSAccounts Update
6th Jul 20237:00 amRNSMAS Holdings invests in HeiQ AeoniQ
29th Jun 20232:16 pmRNSResult of AGM
29th Jun 20237:00 amRNSAGM Statement
6th Jun 20237:00 amRNSNotice of AGM
2nd May 20237:44 amRNSTemporary Suspension of Trading in Ordinary Shares
27th Apr 20233:55 pmRNSTemporary Suspension
13th Jan 20232:09 pmRNSUpdate re. admission of Consideration Shares
12th Jan 20237:00 amRNSCompletion of Acquisition
10th Jan 20237:00 amRNSDirector / PDMR Dealing
6th Jan 20237:00 amRNSDirector / PDMR Dealing
5th Jan 20237:03 amRNSDirector/PDMR Shareholding
4th Jan 20237:00 amRNSTrading Update and Acquisition
14th Dec 20227:00 amRNSIncreased interest in HeiQ Chrisal to 71%

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.